Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Urbani

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Journal of Immunology|July 21, 2006
IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigensCaterina Lapenta, Stefano M Santini, Massimo Spada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2013
Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapyFederica Moschella, Giovanni Fernando Torelli, Mara Valentini, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2019
Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccineCaterina Lapenta, Simona Donati, Francesca Spadaro, et al.
Frontiers in Oncology|June 5, 2023
Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alphaFederica Moschella, Carla Buccione, Irene Ruspantini, et al.
Biomolecules|October 26, 2024
T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 SubjectsIole Macchia, Valentina La Sorsa, Alessandra Ciervo, et al.
Vaccines|September 28, 2024
Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells (IFN-DC)Caterina Lapenta, Stefano Maria Santini, Celeste Antonacci, et al.
Trials|September 4, 2021
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trialEleonora Aricò, Luciano Castiello, Laura Bracci, et al.
Cancer Research|May 3, 2006
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursorsTiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, et al.
Journal of Translational Medicine|May 3, 2015
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanomaCarmela Rozera, Giancarlo Antonini Cappellini, Giuseppina D'Agostino, et al.
Vaccine|February 6, 2008
Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individualsPaola Rizza, Imerio Capone, Francesca Urbani, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Journal of Immunology|July 21, 2006
IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigensCaterina Lapenta, Stefano M Santini, Massimo Spada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2013
Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapyFederica Moschella, Giovanni Fernando Torelli, Mara Valentini, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2019
Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccineCaterina Lapenta, Simona Donati, Francesca Spadaro, et al.
Frontiers in Oncology|June 5, 2023
Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alphaFederica Moschella, Carla Buccione, Irene Ruspantini, et al.
Biomolecules|October 26, 2024
T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 SubjectsIole Macchia, Valentina La Sorsa, Alessandra Ciervo, et al.
Vaccines|September 28, 2024
Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells (IFN-DC)Caterina Lapenta, Stefano Maria Santini, Celeste Antonacci, et al.
Trials|September 4, 2021
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trialEleonora Aricò, Luciano Castiello, Laura Bracci, et al.
Cancer Research|May 3, 2006
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursorsTiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, et al.
Journal of Translational Medicine|May 3, 2015
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanomaCarmela Rozera, Giancarlo Antonini Cappellini, Giuseppina D'Agostino, et al.
Vaccine|February 6, 2008
Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individualsPaola Rizza, Imerio Capone, Francesca Urbani, et al.
Pageof 3